Despite the advancement in HF treatment with the introduction of SGLT2 inhibitors, mineralocorticoid receptor antagonists and other pharmacological treatments supported by current evidence,3 managing the wide array of comorbidities in patients with HFpEF remains a pivotal aspect of improving patient outcomes. The gene discussed is NR3C2; the disease is hydrops fetalis.